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Abstract 
Praziquantel (PZQ) is the drug of choice for treating infection with worms from the genus 
Schistosoma.  The drug is effective, cheap and has few side-effects.  However, despite its use in 
millions of patients for over 40 years its molecular mechanism of action remains elusive.  Early 
studies demonstrated that PZQ disrupts calcium ion homeostasis in the worm and the current 
consensus is that it antagonises voltage-gated calcium channels.  It is hypothesised that disruption of 
these channels results in uncontrolled calcium ion influx leading to uncontrolled muscle contraction 
and paralysis.  However, other experimental studies have suggested a role for myosin regulatory 
light chains and adenosine uptake in the drug’s mechanism of action.  Assuming voltage-gated 
calcium channels do represent the main molecular target of PZQ, the precise binding site for the 
drug remains to be identified.  Unlike other commonly used anti-parasitic drugs, there are few 
definitive reports of resistance to PZQ in the literature.  The lack of knowledge about PZQ’s 
molecular mechanism(s) undermines our ability to predict how resistance might arise and also 
hinder our attempts to develop alternative antischistosomal drugs which exploit the same target(s).  
Some PZQ derivatives have been identified which also kill or paralyse schistosomes in culture.  
However, none of these are in widespread clinical use.  There is a pressing need for fundamental 
research into the molecular mechanism(s) of action of PZQ.  Such research would enable new 
avenues for antischsistosomal drug discovery. 
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Introduction:  Schistosomiasis 
Schistosomes (blood-dwelling parasites of the Schistosoma genus), are the causative agents of 
schistosomiasis (bilharzia), a devastating parasitic disease, second only to malaria with respect to its 
detriment to global health and socio-economic impact [1]. Most cases of schistosomiasis are 
attributable to one of three schistosome species, Schistosoma mansoni, Schistosoma japonicum and 
Schistosoma haematobium, whose habitats are predominantly confined to tropical and sub-tropical 
regions. 
Concerted treatment strategies have resulted in almost total elimination of this disease in Japan, and 
substantial progress has been made in other endemic regions, such as the Caribbean islands, Brazil 
and China [2]. However, despite this progress, schistosome infections are becoming increasingly 
prevalent in previously non-endemic regions. Moreover, the disease burden, morbidity and mortality 
rates in sub-Saharan Africa are still high [3, 4]. Indeed, on a global scale, it is estimated that almost 
800 million people are at risk of schistosome infections, and over 200 million individuals are already 
infected [4]. Of those already infected, a staggering 85 % are located in Africa, resulting in 
approximately 200,000 deaths per annum in sub-Saharan Africa alone [1, 5]. 
Despite these alarming figures, schistosomiasis is still considered a “neglected tropical disease” 
(NTD). This is primarily due to the socio-economic standing of the individuals affected by this 
disease, as infections tend to be confined to poor, rural (and often marginalised) communities [6-9]. 
Furthermore, as schistosomiasis is a chronic disease, causing long-term (and often subtle) 
pathologies, its eradication is perhaps not as high on the priority list as global health initiatives 
directed against other infectious diseases, such as malaria and HIV [2]. Nevertheless, with the advent 
of large-scale treatment interventions in Africa, and new health initiatives in the endemic regions of 
Egypt, it seems that these paradigms may be shifting. 
 
Schistosomes 
Platyhelminthes (flatworms), are a diverse phylogenetic lineage comprising both free-living 
(turbellarian), and parasitic (trematode, monogenean and cestode) clades [10]. Schistosomes belong 
to the trematode (fluke) lineage (Phylum: Platyhelminthes; class; Trematoda; sub-class: Digenea; 
order: Strigeidada; family: Schistosomatidae; genus: Schistosoma), a large sub-group of parasitic 
platyhelminths, which require both a molluscan (intermediate), and vertebrate (definitive) host to 
complete their lifecycle [11, 12]. 
Schistosomes have a complex lifecycle, comprising both free-living and parasitic stages, and 
encompassing a remarkable series of morphological and physiological changes [12] (Fig. 1). Briefly, 
schistosome eggs are either shed in the urine (S. haematobium) or faeces (S. mansoni and S. 
japonicum) into freshwater lakes and rivers, where they hatch, releasing miracidia. Miracidia invade 
intermediate freshwater snail hosts, where they multiply, undergoing several rounds of asexual 
reproduction to transition from the larval sporocyst stage, to the infective cercarial stage (a process 
which takes approximately 4-6 weeks) [13]. Free-swimming cercariae are then released from the snail, 
back into the water where they encounter their definitive mammalian host, typically humans bathing 
in freshwater lakes, pools or rivers. 
Infective cercariae penetrate the skin of their human host (using digestive enzymes), and upon doing 
so, shed their tails to become schistosomula (Fig. 1). Schistosomula reside within the skin for over 24 
hours (a period often referred to as the skin stage) [14], before making their way through the dermal 
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tissue, to the veins. Migratory juveniles then travel to the lungs via the pulmonary artery (5-6 days 
post-infection), where they are now referred to as “lung schistosomula” [15]. At this point, 
schistosomula re-enter the circulatory system and travel to the liver, where they begin to feed on 
blood, and grow rapidly for 8-10 days [16].  
From here, immature worms migrate to the venous plexus of the bladder (S. haematobium), or the 
superior mesenteric veins of the intestine (S. mansoni and S. japonicum), where they mature into 
adults (approximately 5-7 weeks post-infection) [13]. Upon reaching sexual maturity, male and female 
worms couple and reproduce (Fig. 1), allowing the female to produce hundreds to thousands of eggs 
per day [13]. Eggs are then excreted via the bladder (S. haematobium), or the lumen of the intestine 
(S. mansoni and S. japonicum), so that the infection cycle can start anew. 
However, such prolific egg production means that eggs frequently become trapped in host tissues. 
Indeed, the pathologies associated with schistosomiasis are predominantly caused by eggs lodged in 
the intestines or liver (S. mansoni and S. japonicum) or in the bladder/urogenital system (S. 
haematobium) [17]. The host pro-inflammatory immune response to egg antigens (and those of 
migratory juveniles) results in acute schistosomiasis, or ‘Katayama syndrome’, which manifests as 
fever, myalgia, headache, fatigue, and abdominal pain [18]. Whereas the granulomas that form 
around these eggs can result in a broad spectrum of chronic pathologies, ranging from anaemia and 
stunted growth, to infertility, tissue fibrosis, portal hypertension, haemorrhaging and squamous cell 
carcinoma [13]. In certain instances, egg granulomas can also be found in the brain and spinal cord of 
infected individuals, leading to severe neurological complications [19].  
Although S. mansoni, S. japonicum and S. haematobium share considerable similarity in terms of their 
lifecycle, development and transmission, there exist some subtle (yet notable) differences between 
the three schistosome species, particularly in terms of their geographical distribution and 
intermediate host availability. For example, S. mansoni and S. haematobium share an overlapping 
habitat in sub-Saharan Africa and the Middle East; whereby S. haematobium parasitizes freshwater 
snails of the Bulinus genus, and S. mansoni parasitizes snails of the Biomphilaria genus. Indeed, the 
broad geographical distribution of Biomphilaria snails means that S. mansoni isolates can be found 
further afield, with habitats in the Caribbean islands and South America [13]. Conversely, S. japonicum 
isolates are localised to Asia (including Indonesia, mainland China and the Philippines), where they 
parasitize freshwater snails of the Oncomelania genus [13].   
Due to their differential localisation in host tissues, Schistosoma spp. also display distinct diagnostic 
traits and pathologies. For example, urinary tract schistosomiasis (caused by infection with S. 
haematobium), is often diagnosed by the presence of blood in the urine, and is associated with a 
higher risk of squamous-cell bladder carcinomas [20], and infertility [13]. Whereas intestinal 
schistosomiasis (caused by infection with S. mansoni or S. japonicum), can often go undiagnosed due 
to an absence of consistent diagnostic symptoms, ranging from the presence of blood in the stools, 
abdominal pain and cramps, to hepatomegaly (enlarging of the liver), and/or splenomegaly 
(enlarging of the spleen) [6]. 
 
Treatment of schistosomiasis 
In the absence of an effective vaccine against schistosomiasis, treatment strategies centre on the 
administration of the anthelmintic drug, praziquantel (PZQ) (Fig. 2), a pyrazino-isoquinoline derivative 
[21, 22]. PZQ is an effective, and relatively inexpensive drug with few side effects, with activity against 
a broad spectrum of parasitic flukes and tapeworms [23-26]. Indeed, due to its efficacy against all 
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forms of human schistosomiasis [27], PZQ has largely supplanted other antischistosomal compounds, 
such as oxamniquine (OXA) (Fig. 2), a tetrahydroquinoline derivative with activity against S. mansoni, 
but not against the other members of the Schistosoma genus [28]. This drug was shown to inhibit the 
synthesis of DNA, RNA and proteins in S. mansoni suggesting that its target may be one (or more) of 
the proteins involved in nucleic acid synthesis [29].  Later work demonstrated that it binds directly to 
DNA, probably following activation by a parasite-specific sulphotransferase enzyme (SmSULT-OR) [30, 
31].  The enzyme from S. mansoni processes the drug more efficiently than the equivalent enzyme 
from other Schistosoma species, thus explaining why OXA is more effective in S. mansoni [32].  
Mutations which result in loss of function in S. mansoni SmSULT-OR can result in resistance to OXA 
[33].  The availability of structures of the sulphotransferase enzyme from S. japonicum and S. 
hematobium mean that rational, structure-based, medicinal chemistry can now be applied to the 
development of OXA derivatives which are effective against all these species in addition to S. mansoni 
[32]. 
The recommended dose of PZQ is approximately 40-60 mg kg-1 body weight, with the lower dose 
generally sufficient for treatment of S. mansoni and S. haematobium infections, and the higher dose 
recommended for treatment of S. japonicum. Upon administration of this drug, cure rates range 
between 83 – 89 % for S. haematobium, 79 – 87 % for S. mansoni and are approximately 86 % for S. 
japonicum [34]. 
In addition to its antischistosomal activity, praziquantel can be used to treat diseases caused by other 
trematode infections, such as clonorchiasis (caused by infection with the Chinese liver fluke, 
Clonorchis sinensis), and opisthorchiasis (caused by infection with the Southeast Asian (or 
carcinogenic) liver fluke, Opisthorchis viverrini). Cestodes, such as the beef tapeworm, Taenia 
saginata, and the pork tapeworm, Taenia solium, are also susceptible to PZQ [34]. There are also 
veterinary uses of the drug – for example in fish farming, companion animals and agriculture [35-38].  
Interestingly, there is also a considerable “grey literature” on the use of PZQ to clear ornamental fish 
tanks etc of infestation by planarians and other worms.  In general, this has only been subject to 
limited rigorous scientific investigation, but it does represent a significant use of the drug in the more 
developed parts of the world [39]. 
Thus, due to its efficacy and versatility, praziquantel has become the “treatment of choice” against 
schistosomiasis, and numerous other trematode/ cestode infections. However, this drug is not 
without its limitations.  For example, PZQ is of limited use in the treatment of hydatid disease (a 
zoonotic disease caused by infection with Echinococcus spp.) [40], and is largely ineffective against 
fasciolosis, a parasitic disease caused by liver flukes of the Fasciola genus, including Fasciola 
gigantica and Fasciola hepatica [41-43]. Moreover, a major shortcoming of PZQ lies with its biphasic 
efficacy against schistosomes [44]. Cercariae and “skin stage” schistosomula are highly susceptible to 
PZQ treatment, as are adult worms. Conversely, juveniles are less sensitive to PZQ, and largely 
refractory to this drug around 3-4 weeks post-infection, gradually regaining full susceptibility 6–7 
weeks after infection [24, 45, 46]. This drawback has serious implications for the treatment and 
control of schistosomiasis, as, depending on the stage of infection, chemotherapy against the 
juvenile worm can lead to apparent drug failure, lower cure-rates, prolonged infective periods, and 
the requirement for multiple rounds of treatment [25]. 
In the absence of an effective vaccine to protect against schistosome infection, some countries and 
regions have established mass drug administration programmes (MDA) [47].  In a typical MDA 
programme, the large groups of people (often vulnerable groups such as children) are offered 
prophylactic doses of PZQ.  This strategy works in an analogous way to “herd immunity” resulting 
from wide-spread vaccination for other infectious diseases.  In areas where schistosomiasis is 
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endemic, the release of urine or faeces into communal water ensures that infected individuals 
expose others to the risk of the disease.  In an MDA programme, the majority of individuals suffering 
from schistosomiasis will be cured.  This limits the release of schistosomes into the environment.  
Furthermore, non-infected individuals will have PZQ in their system and so are less likely to become 
infected if exposed to the parasite.  Thus, the cycle of infection can be broken.  There is some 
evidence that individuals treated with PZQ as part of a MDA programme are more likely to develop 
some limited immunity towards future infections.  Treatment with PZQ results in a reduction in the 
immunomodulatory effects of the parasite and the release of tegumental antigens [48].  However, 
there is a risk that over a longer time period reducing the number of people infected will result in a 
lower fraction of the population having partial immunity [49].  MDA programmes can be highly 
successful [50].  This success rests on the relatively low cost of the drug (which enables very large 
numbers of people to be offered it cost-effectively), the generally limited side-effects (which 
removes one possible cause of non-compliance in the targeted populations) and the lack of 
widespread resistance to PZQ (see below).  Concerns have been raised that such wide-spread use of 
the only effective drug to treat schistosomiasis will increase the selective pressure for the 
development of resistance (in a manner analogous to the emergence of antibiotic resistance in 
bacteria) [47, 51]. 
 
Praziquantel:  pharmacology 
Praziquantel, marketed as “Biltricide” (Bayer HealthCare Pharmaceuticals Inc., Germany), is the 
generic name for 2-(cyclohexylcarbonyl)-1,2,3,6,7, 11b-hexahydro-4H-pyrazino [2, 1-a] isoquinolin-4-
one (Fig. 1.3). PZQ was originally developed as a novel tranquiliser.  However, it proved to be less 
effective than existing compounds and was passed from Merck to Bayer for testing as a veterinary 
medicine which showed it to be highly effective in the treatment of schistosomiasis in a range of 
mammals [52, 53].  Following successful trials in animals it was re-considered as a human medicine 
and entered clinical and field trials which demonstrated the drug’s efficacy and tolerability [54, 55].  
In its commercial form, PZQ exists as a racemic mixture of laevo R(-), and dextro S(+) enantiomers, of 
which only the R-enantiomer exhibits antischistosomal activity [56-59].  In general, the drug is 
formulated and marketed in the racemic mixture.  This is largely due to the reduced cost of producing 
the drug in this form [60].  However, there is some evidence that side-effects would be reduced by 
using the purified R-enantiomer [61].  The bitter taste of the drug is also largely ascribed to the S-
enantiomer [62].  Consequently, efforts have been made to synthesise enantiomerically pure R-
praziquantel or to design effective purification of this isomer from the racemic mixture [63-67].  The 
reasons for the greater effectiveness of the R-enantiomer are not clear.  The most obvious explanation 
is that only this isomer is able to bind to the target, a situation which is common for chiral drugs.  This 
arises because the binding sites for molecules in proteins are themselves generally chiral and will thus 
have different affinities for the two enantiomers.  In the absence of clear identification of the target 
biomolecule and the location of the specific binding site, it is currently impossible to verify this 
hypothesis.  It is also possible that the two molecules are processed differently (or with different 
efficiencies) by the host and/or parasite metabolic systems.  Again, this would arise from the binding 
of the drug to chiral active sites in the enzymes which catalyse these metabolic processes. 
PZQ is classed as a “Class II” drug in the Biopharmaceutics Classification Systems (BCS), signifying a low 
solubility in water, and a high permeability in the gastrointestinal (GI) tract [68]. Hence, the dissolution 
rate of this drug represents a limiting step in its absorption [69], requiring higher doses than may 
otherwise be necessary [26].  
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Upon first pass metabolism in the liver, PZQ undergoes extensive metabolism by cytochrome P-450 
enzymes (2B1 and 3A), to form numerous derivatives and metabolites [70-72], with rapid 
disappearance from the circulatory system (plasma half-life ≈ 1-3 h), and clearance from the body 
within approximately 24 hours [24]. One of the main metabolites resulting from this 
biotransformation, a polar trans-cyclohexanol derivative (trans 4-OH-PZQ), has an approximate 4 to 
10-fold lower efficacy than PZQ on S. mansoni [26]. Thus, the bioavailability of PZQ can be increased 
when administered with inhibitors of cytochrome P-450, such as cimetidine [73, 74]. Bioavailability 
can also be increased when administered with food (especially carbohydrates) [75, 76], but is 
substantially reduced upon simultaneous administration of antiepileptic drugs, such as carbamazepine 
or phenytoin, or upon treatment with corticosteroids, such as dexamethasone [77, 78].  Side-effects 
are generally considered to be minimal, but some caution may be required if the patient has other 
serious conditions such as heart failure [79]. 
 
Praziquantel:  mechanism of action 
Despite the widespread use of PZQ for over 40 years, its cellular target and mechanism of action 
remain elusive. However, evidence suggests that PZQ acts to disrupt calcium-mediated processes in 
adult schistosomes, potentially through antagonism (or partial agonism which results in dysregulation) 
of the parasite’s voltage-gated calcium (Cav) channels and/or molecules which interact with and 
regulate these channels [25, 80, 81]. These hypotheses are largely based on the observed effects of 
this drug. 
Early studies, conducted in vitro, demonstrated that PZQ altered the membrane permeability of adult 
S. mansoni and S. japonicum worms, causing rapid calcium influx, sustained muscle contractions and 
profound disruption to the tegument [21, 82, 83], a syncytial structure which forms the outer layer of 
the parasite, acting as both a protective shield, and dynamic interface with the host environment [84]. 
These effects were dose dependent, and were inhibited in the absence of calcium ions, implying a 
mechanistic link between PZQ activity and calcium-mediated processes [21, 85]. Thus, in physiological 
terms, PZQ-induced vacuolation and blebbing of the tegument is thought to lead to the increased 
exposure of surface antigens that can be recognized, and attacked by the host immune system. In 
addition, sustained contraction of the worm musculature results in the paralysis of the parasite, 
detachment from host tissues, and subsequent expulsion from the host [56, 86]. These early 
experiments were replicated with other PZQ-susceptible flatworms, such as the trematodes C. sinensis 
and O. viverrini [87], and numerous cestode species, including members of the Hymenolepis and 
Taenia genera [88], but not with the PZQ-refractory trematode, F. hepatica, whose unusually thick 
and robust tegument may (in part) negate the effects of this drug [83].  
Indeed, subsequent studies revealed that the tegument was likely to play an integral role in the PZQ 
mechanism of action, as evidenced by comparative analyses between intact and detegumented S. 
mansoni adult male parasites. For example, Blair and co-workers demonstrated that PZQ produced a 
dose-dependent tonic contraction in intact S. mansoni worms, when the parasites were bathed in 
standard RPMI media. However, when the medium was supplemented with a high magnesium: 
calcium ion ([Mg2+]:[Ca2+]) ratio, tonic contractions were inhibited, resulting in a PZQ-dependent 
biphasic contraction and flaccid paralysis (no response to subsequent stimuli which would be expected 
to cause muscle contraction), indicating that an extracellular Ca2+ source was required for the full 
effects of this drug, in vitro [89]. In contrast, detegumented worms, whilst still responding to PZQ, 
exhibited a single phasic contraction when incubated in elevated [Mg2+] media [89]. Furthermore, 
when calcium ions were removed from the medium, PZQ evoked a transient response in intact worms, 
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but did not evoke a response in detegumented worms until the medium was reconstituted with 
calcium ions. This implied that the tegument and sarcoplasmic membranes both contained PZQ-
sensitive sites, but the tegument was required for full response to this drug [89]. As such, the authors 
proposed that PZQ altered the activity of calcium channels, located in the tegument and muscles of 
schistosomes. 
Cav channels are typically large, multi-domain complexes, consisting of a pore-forming α1 subunit 
(which defines the functionality and pharmacology of the channel), and a subset of smaller auxiliary 
subunits, including the β and α2δ subunits (Fig. 1.6), which act to modulate the activity of the channel, 
whilst directing expression to the plasma membrane [90, 91]. Calcium channels are categorised 
according to the current gated by the α1 subunit, and can be classed as either high voltage activated 
(HVA) channels, which open in response to strong membrane depolarization (including Cav1 and Cav2 
channel sub-types); or low voltage activated (LVA) channels, which respond to weak depolarization 
(including the Cav3 channel sub-type) [91-93]. HVA channels can be further defined by their 
localisation to certain tissue types (Table 1.1), and their sensitivity to various drugs. L-type channels 
are sensitive to dihydropyridines, such as nifedipine, verapamil, nicardipine and nemadipine. Whereas 
non-L-type channels are refractory to dihydropyridines, but can be further divided into N, R, P/Q and 
T-types based on their differing sensitivities to certain toxins [91, 94]. 
Furthermore, as the C-terminal region of the α1 subunit is also believed to function as a binding site 
for (calcium-free) apo-calmodulin. Evidence suggests that calmodulin is constitutively tethered to  
the Cav channel, allowing for a rapid response to changes in cellular calcium ion concentration [95-
97]. However, the location of the tethering site remains controversial, with some studies implicating 
the IQ motif [98], and others implicating the pre-IQ domain [97], or a C-terminal site in proximity to 
and/ or encompassing the two domains [96]. 
The hypothesis that PZQ acts (at least in part) through voltage-gated calcium channels was supported 
by a series of studies by Kohn and co-workers [99-101]. In these experiments, schistosome voltage-
gated calcium (Cav) channels were shown to contain an unusual Cav channel β subunit (termed the 
variant β subunit, or “βvar”), which was structurally distinct from its mammalian homologues, and 
unique to Platyhelminthes [81]. The authors demonstrated that this variant subunit could confer PZQ-
sensitivity to an otherwise insensitive mammalian Cav channel α1 subunit when heterologously 
expressed in Xenopus oocytes, a characteristic attributed to the absence of two serine residues within 
a conserved region of the protein, termed the β interaction domain (BID), which typically function as  
protein kinase C (PKC) phosphorylation sites [101]. At the time, the BID was believed to contact the 
α1 subunit (the pore-forming component of the channel), playing an integral role in channel 
regulation, thereby providing a putative mechanism by which PZQ could elicit its effects on calcium 
homeostasis [102]. However, the X-ray crystal structure of a mammalian Cav channel complex 
revealed that the BID was buried within the matrix of the protein, and did not contact the α1 subunit 
[103]. Thus, the method by which the variant β subunit mediated its effects on the α1 subunit 
remained unresolved [81]. Moreover, as subsequent studies revealed that the sequence and 
expression levels of the β variant were seemingly unaltered between PZQ-susceptible adult S. mansoni 
worms and PZQ-refractory juveniles [81, 104, 105], this cast further doubt on the role of the variant β 
subunit in the PZQ mode of action.  
Nevertheless, these observations do not eliminate the possibility that schistosome Cav channels 
serve as a molecular target for PZQ. It should be noted that although juvenile worms can withstand 
drug concentrations that are lethal to adult parasites, they still respond to PZQ treatment with 
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increased calcium influx and the onset of muscular contractions [106]. Thus, whereas Cav channels 
may serve as an initial receptor for this drug, its antischistosomal activity may be mediated by 
downstream components, which are differentially expressed between PZQ-susceptible and PZQ-
refractory parasites [81].  
The notion that Cav channels function as determinants of PZQ-susceptibility has been further explored 
in other species of Platyhelminthes; most notably in the planarian, Dugesia japonica.  Planarians (free-
living turbellarian flatworms), have been extensively studied due to their regenerative properties 
[107]. For example, upon amputation of the head and tail, D. japonica trunk fragments can regenerate 
a complete body plan within 5 to 7 days, retaining the anterior–posterior polarity of the worm. 
However, when this organism is exposed to PZQ, the regeneration process takes a rather unexpected 
turn: the anterior-posterior axis of the worm is duplicated, leading to a two-headed organism with a 
duplicated (and integrated) central nervous system (CNS), and organ systems [108]. As with 
schistosome species, D japonica encodes two Cav β subunits; a “conventional” β subunit (with 
homology to mammalian β subunits), and a variant sub-type lacking two conserved serine residues in 
the BID domain, which shares approximately 34 % sequence identity with “Cav βvar” (the variant 
subunit previously implicated as a putative molecular target of PZQ in S. mansoni worms). Thus, Nogi 
and co-workers set out to test whether these Cav channel subunits were involved in the observed 
effects of PZQ on the D. japonica regeneration process.  Using RNA interference (RNAi) technology, 
they demonstrated that silencing of the genes encoding either Cav β subunit antagonised the ability 
of PZQ to produce bipolar (two-headed) worms. Moreover, at higher doses of PZQ, RNAi-silenced 
worms displayed increased resistance to this drug in lethality assays, providing further indication that 
the components of platyhelminth Cav channels played a role in the PZQ mechanism of action [108]. 
Interestingly, subsequent RNAi experiments directed against the pore-forming, α1 subunits of the D. 
japonica Cav channel complex [109], demonstrated that RNAi-silencing of one such subunit (Cav1A), 
resulted in a loss of the PZQ-mediated bipolar phenotype, prevented PZQ-mediated calcium uptake in 
a neuronally enriched cell fraction, and prevented PZQ-mediated inhibition of wnt-1 and wnt11-5 (the 
genes regulated by hedgehog signalling) [110]. Whereas RNAi-mediated knockdown of another Cav 
α1 subunit (Cav1B), significantly increased the ability of PZQ to miscue tissue regeneration [109]. 
These analyses highlighted two intriguing observations. First, the authors reasoned that PZQ was able 
to selectively activate the Cav1A α1 subunit, thereby inhibiting neuronal hedgehog signals and 
dysregulating tissue regeneration [109]. Second, as PZQ action was seemingly antagonised by calcium 
influx through Cav1B, this suggested that PZQ-sensitivity was modulated by a complex interplay 
between two opposing regulatory mechanisms [109].   
Similar phenotype assays have not yet been conducted in schistosomes.  However, if these findings 
are broadly applicable to parasitic platyhelminths, then (in terms of future drug-development 
studies), agonists of the Cav1A channel sub-type may be expected to be enhance PZQ activity, or 
convey a PZQ-like phenotype in the worm, whereas antagonists of the Cav1B channel sub-type may 
be expected to sensitise the worm to PZQ [109, 111]. 
 
Interestingly, there is little structural similarity between PZQ and other drugs which are 
hypothesised to target mammalian voltage-gated calcium channels.  A number of these drugs are 
used in humans, primarily to control hypertension [112].  These include nifedipine, verapamil, 
nicardipine and nemadipine.  In general, these are described as calcium channel “blockers” because 
they inhibit or antagonise the uptake of calcium ions by the cell.  This is in contrast to well-
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documented effect of PZQ, namely the uncontrolled influx of the ion.  Nifedipine targets mammalian 
L-type voltage-gated calcium channels, but also has activity against some other sub-types [113, 114].  
This drug does have anti-schistosomal activity resulting in similar anatomical and physiological 
dysfunction to the administration of PZQ [115].  Verapamil mildly inhibits the hatching of S. mansoni 
eggs and disrupts the regulation of muscle contraction by neuropeptides [116, 117].  Nicardipine has 
the same effect on the regulation of muscle contraction [116].  Verapamil also disrupts the worm’s 
tegument in a similar manner to PZQ, but has a different effect overall effect on the worm:  while 
PZQ causes rapid muscle contraction resulting in the worm forming a tight coil, verapamil causes the 
worm to adopt a long, gentle spiral form [118].  Taken together these studies demonstrate that 
voltage gated calcium channels represent a viable target for antischistosomal drugs.  While it is 
unlikely that any current anti-hypertensive drugs will be suitable for repurposing as anthelminthics, 
these pharmacological experiments demonstrate that calcium channel blocking in schistosomes 
results in morphological damage, physiological disruption and often death of the worm.  Thus, 
further characterisation of the biochemistry and pharmacology of schistosome voltage-gated 
calcium channels may well be useful, even if they ultimately prove not to be the main target of PZQ.  
While these calcium channel blockers generally had similar effects on schistosomes to PZQ, there 
were key differences, suggesting that PZQ has a different molecular mechanism of action.  This may 
be related to its ability to cause rapid calcium ion influx rather than to “block” calcium channels.  It is 
entirely possible that PZQ binds at a different site to the channel blockers, or even to a different 
subunit. 
 
Ca2+ signalling in schistosomes 
Despite the wealth of information available on the intricacies of mammalian Ca2+ signalling pathways, 
relatively little is known of the processes that govern these pathways in parasitic flatworms. Two 
calmodulin proteins have been identified in S. mansoni, designated SmCaM1 and SmCaM2, which 
share considerable sequence identity to mammalian calmodulin [119]. These proteins display distinct, 
yet overlapping expression profiles in the early larval stages of the parasite’s lifecycle. RNAi-mediated 
knockdown of either gene suggests that they play an important role in larval development [119]. 
Antagonism of S. mansoni calmodulin results in substantial disruption to the organism’s tegument and 
muscles [120] and egg hatching is also blocked by calmodulin antagonists [117]. In mammals, the 
interaction between calmodulin and voltage-gated calcium channels has been extensively investigated 
and this protein is known to modulate channel activity in response to cellar calcium ion concentrations 
[121].  However, comparatively little is known about the interaction of calmodulin with targets such 
as schistosome Cav channels or the functional consequences thereof. 
Given that S. mansoni encodes an atypical complement of Cav channel subunits (including four pore-
forming α1 subunits, two auxiliary α2 δ subunits and two modulatory β subunits) [122], which each 
display distinct structural/ sequence motifs, distinguishing them from mammalian Cav channels (or 
those of some other invertebrates) [81, 123], mapping their interaction with CaM would be an 
invaluable first step in elucidating the mechanisms by which schistosomes regulate calcium 
homeostasis. Moreover, schistosomes contain an unusual family of calcium binding proteins, which 
combine an EF-hand domain at their N-terminus and a dynein light chain-like (DLC-like) domain at 
their C-terminus [124-126]. The biological function of these “EF-hand/ DLC-like domain” proteins is 
currently unknown, however, their structural similarity to CaM (at the N-terminus) is consistent with 
a role in calcium signalling, or calcium-mediated processes, whereas their structural similarity to 
dynein (at the C-terminus), suggests that some of these proteins could be involved in cytoskeletal 
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transport. Indeed, as one family member (SmTAL3) was isolated in a large, multi-protein complex at 
the S. mansoni tegument, which was also shown to contain dynein [127], it is possible that some of 
these proteins are also required for a structural role at the tegument.  Intriguingly, at several members 
of the SmTAL family (SmTAL1 or Sm22.6, SmTAL4, SmTAL5 and SmTAL8) interact with PZQ, whereas 
there is no evidence for the drug interacting with calmodulin or antagonising any processes mediated 
by this protein [120, 126, 128]. 
 
Alternative hypotheses for PZQ action 
Cav channels serve as important entry sites for extracellular calcium, mediating the processes that 
define electrical excitability in cells and regulating neurotransmission [129]. Thus, given that the 
observed effects of PZQ on adult schistosomes, in vitro, are consistent with the disruption of calcium 
homeostasis and subsequent dysregulation of the neuromuscular system [22], the body of (albeit, 
indirect) evidence points towards a role for these membrane-bound protein complexes in the PZQ 
mechanism of action; a theorem coined the “Ca2+ hypothesis” of PZQ action [111]. However, due to 
difficulties in the functional expression of schistosome Cav channel α1 subunits, these hypotheses 
have yet to be explicitly tested [81]. As such, there remains a possibility that any disruption of calcium 
homeostasis is merely a secondary effect of PZQ binding to an unrelated molecular target [102]. 
Indeed, a study by Pica-Mattoccia and co-workers demonstrated that when adult, male S. mansoni 
worms were incubated in a medium containing radioactive carbon, PZQ treatment resulted in rapid 
calcium uptake from the medium (an observation which is consistent with previous studies) [21, 106]. 
However, when these worms were pre-treated with cytochalasin D, a compound previously shown to 
supress the antischistosomal effects of PZQ [130], parasites not only survived exposure to PZQ, but 
also underwent an increase in PZQ-induced calcium uptake [106] thereby implying that increased 
calcium influx was not correlated with the antischistosomal effects of this drug in vitro. 
Thus, several alternatives to the so-called “Ca2+ hypothesis” of PZQ action have been proposed. For 
example, given that cytochalasin D acts to depolymerise the actin cytoskeleton in mammalian systems 
[106, 130], one might reason that its inhibitory effect on the antischistosomal activity of PZQ could 
signify an overlapping binding site between the two compounds. Interestingly, actin has been 
implicated as a possible molecular target for PZQ in adult S. mansoni worms. Pull-down assays 
(whereby PZQ was immobilised on a cellulose acetate membrane), demonstrated that this drug bound 
a ~45 kDa protein species consisting predominantly of schistosome actin, when a Triton-insoluble 
extract of S. mansoni surface membrane antigens was applied [131]. However, that actin functions as 
a potential target for PZQ remains controversial; subsequent studies, using affinity chromatography, 
indicated that actin bound not only to immobilised PZQ, but also the unconjugated support used to 
affix PZQ to the column [132], implying that binding was non-specific, and merely an artefact of the 
high abundance of actin in S. mansoni extracts. 
Nevertheless, several studies have provided viable alternatives to the “Ca2+ hypothesis” of PZQ action. 
It has been proposed that PZQ may inhibit the uptake of adenosine, an essential nucleoside which 
cannot be synthesised by the parasite [133]. Whereas peptide-mapping showed that PZQ bound to 
the N-terminal region of S. mansoni myosin light chain (SmMLC), triggering its phosphorylation [134]. 
(Note, myosin light chains have similar structures to calmodulin, although the majority are not 
regulated by direct binding to calcium ions [135].) Given that MLC proteins play an essential role in 
smooth muscle contraction [136], and that their phosphorylation is associated with increased calcium 
mobilisation [137], the authors proposed that PZQ-induced phosphorylation of SmMLC may account 
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for the observed effects of this drug on schistosomes, potentially playing an important role in the PZQ 
mechanism of action [134]. 
Early structural work demonstrated that PZQ could complex with S. japonicum glutathione S-
transferase (SjGST), an essential detoxification enzyme in the parasite and putative vaccine target. As 
PZQ was shown to bind in proximity to the catalytic site of SjGST, the authors proposed that this 
interaction could have an inhibitory effect on enzyme function [138]. However, subsequent kinetic 
studies utilising a variety of model substrates found little evidence to support this hypothesis [139]. 
PZQ also has at least one molecular target in the host.  Recent work has established that the drug acts 
as a partial agonist of the serotoninergic 5HT2B receptor [140].  This receptor helps control vascular 
tone resulting in vasoconstriction [141].  These actions may promote the movement of worms 
paralysed by PZQ to the liver where they are eliminated before they can lay eggs [140]. 
Interestingly, the efficacy of PZQ has also been linked to various antigenic proteins. Given that PZQ 
acts to disrupt the tegument, thereby exposing parasite antigens to the host immune system [86], one 
may reason that antigens on (or near) the tegumental surface could aid in immune system recognition, 
amplifying the effects of this drug [25]. Accordingly, several antigenic targets have been identified in 
schistosomes, which appear to have a synergistic effect on the antischistosomal activity of PZQ; 
including a 27 kDa esterase-like protein in S. mansoni [142], a 200 kDa S. mansoni glycoprotein [143], 
and a 24 kDa tegument antigen in S. japonicum (SjTP22.4) [144], which shares homology with the 
SmTAL protein family in S. mansoni [125]. 
Finally, one must also consider the possibility that the drug has multiple targets. Evidence suggests 
that PZQ is likely to have multiple receptors [111], which may explain why its mechanism of action 
has been so difficult to delineate. Ironically, whilst the existence of multiple molecular targets for 
this drug may be problematic for the rational design of novel anthelmintics, this phenomenon may 
explain why schistosomes have yet to develop clinically-relevant resistance to PZQ.  A variant to the 
multiple targets hypothesis is that PZQ targets and disrupts an interaction between two or more 
proteins.  In the simplest form, the drug might bind at the interface between two proteins and 
sterically hinder the interaction.  Alternatively, binding of PZQ to one protein might result in 
allosteric changes to the structure which reduces the affinity for a specific protein partner.  Given 
the well-documented effects of PZQ on calcium homeostasis, an obvious potential protein-protein 
interaction target would be one of the complexes involved in calcium uptake or storage.  An 
attractive possibility would be the calmodulin-voltage-gated ion channel interaction (which, under 
certain circumstances in mammals, acts to down-regulate calcium ion uptake).  Assuming that a 
similar mechanism operates in schistosomes, antagonism of this interaction would result in 
dysregulation of calcium uptake causing increased cellular concentrations of the ion.  However, the 
lack of evidence that PZQ affects calmodulin-mediated processes in schistosomes [120], suggests 
that this (relatively simple) mechanism is unlikely to operate.  One, as yet unexplored, possibility is 
that some SmTAL proteins can function analogously to calmodulin in the regulation of voltage-gated 
calcium channels.  If so, the binding of PZQ to SmTAL1 may be a pharmacologically relevant event 
which results in the disruption of protein complexes involved in the regulation of calcium uptake. 
 
Drug resistance 
Widespread resistance to PZQ has not yet emerged. However, resistance has been generated in the 
laboratory [145], and there are numerous examples of other parasitic worms that have evolved 
resistance to commonly used anthelmintics. Certain field isolates of the liver fluke, F. hepatica, for 
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instance, possess reduced susceptibility to the drug, triclabendazole (TCBZ) [146], which may be the 
result of a single amino acid substitution in the ABC multidrug transporter, P-glycoprotein (Pgp) [147], 
and several species of gastrointestinal nematodes have developed resistance to the broad-spectrum 
anthelmintic, ivermectin [148]. Thus, the emergence of clinically-significant resistance to PZQ appears 
to be inevitable in the medium to long term. 
In support of this prediction, reports of lower cure rates, and/or resistance to PZQ have been recorded 
in Senegal, Kenya, China, Egypt and Brazil [25, 149]. For example, after an outbreak of schistosomiasis 
in Northern Senegal [150], infected individuals were treated with the recommended dose of PZQ (~ 
40 mg kg-1 body weight); cure rates of 18-36 % were recorded, compared to a 79 % cure rate with OXA 
[151, 152]. A subsequent laboratory (murine) model based on the Senegal S. mansoni field isolate 
demonstrated that the parasite had a longer prepatent phase than Puerto Rican or Kenyan lab strains, 
which implied that the observed resistance to PZQ could be an artefact of high-intensity infection/re-
infection, or drug failure, due to chemotherapy against the juvenile fluke [149]. However, when 8-
week-old infections with this isolate were treated with PZQ or OXA under controlled laboratory 
conditions, chemotherapy resulted in a 50 % or 98 % reduction in worm burden, respectively [153], 
demonstrating that the Senegal strain was fully susceptible to treatment with OXA, but had an 
increased tolerance to PZQ. Given that both drugs are ineffective against juvenile S. mansoni parasites, 
this implied that increased resistance to PZQ could not be solely attributed to the developmental stage 
of the parasite at the time of treatment [153]. 
A similar murine model was developed in Egypt, based on S. mansoni isolates collected from 
individuals who had failed three successive rounds of chemotherapy with PZQ. After propagation in 
mice, isolates exhibited a 3 to 5-fold lower susceptibility to drug treatment [154, 155]. Moreover, 
subsequent studies revealed that some of the isolates retained this trait after multiple passages in the 
absence of PZQ, suggesting that sustained selective pressure was not required for the maintenance of 
the PZQ-resistant phenotype [156, 157]. Interestingly, as isolates that retained reduced susceptibility 
to PZQ exhibited a reduction in reproductive fitness (as measured by a decrease in cercariae 
production, in vitro) [156], this suggested that the biological “cost” of resistance may limit the spread 
of the resistant phenotype [149].  
Without a definitive molecular target, it is difficult to speculate how resistance to PZQ might occur. 
However, one might start by examining the mechanism by which S. mansoni worms develop resistance 
to oxamniquine (OXA) [158]. OXA is highly effective against (adult) S. mansoni worms, but not against 
S. haematobium or S. japonicum [27]. This is because the drug is activated by a sulfotransferase 
enzyme which is absent in most schistosome species [31]. The active form of the drug acts as an 
alkylating agent of parasite DNA, inhibiting nucleic acid synthesis [30]. As resistance to this drug is 
carried on a single autosomal recessive allele, organisms that inherit this gene do not express the 
sulfotransferase enzyme and are therefore unable to activate the drug [27]. However, as reduced 
sensitivity to PZQ appears to be a dominant trait [159, 160], the mechanism of resistance to PZQ is 
unlikely to follow a similar pattern of inheritance. Moreover, S. mansoni parasites subjected to 
selective drug pressure in the laboratory, exhibited experimentally-induced resistance to PZQ, but no 
reduction in sensitivity to OXA (and vice versa), thereby indicating that drug resistance was induced 
via different mechanisms [145].  Alternatively, resistance might arise through enhanced removal of 
PZQ in a mechanism analogous to the likely resistance mechanism to TCBZ in F. hepatica [147]. 
 
New treatment strategies 
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Despite the fact that clinically-relevant resistance to PZQ has not yet emerged, over-reliance on a 
single drug to treat schistosomiasis (with no alternatives in the pipeline), places us in a rather 
precarious position.  Analysis of the global changes that occur following PZQ treatment (via 
transcriptomics, proteomics or DNA sequencing methodologies), may help with this endeavour, by 
identifying molecules or pathways involved in the PZQ mechanism of action [149]. Moreover, a similar 
rationale could be applied to study PZQ-susceptible versus PZQ-resistant isolates, or changes in the 
gene expression profiles of different lifecycle stages with variable susceptibility to this drug [105]. For 
example, a microarray study by Hines-Kay et al. which detailed changes to the adult and 
schistosomulum S. mansoni transcriptome following exposure to PZQ, identified several molecular 
pathways which may be differentially regulated upon treatment with this drug [161]. Based on these 
data, the authors proposed a possible role for multidrug transporters in the PZQ mechanism of action, 
as well as implicating various molecular components of calcium-mediated processes (such as 
calmodulin and Cav channel subunits), apoptosis and stress-related protein [161]. Furthermore, a 
comparison of gene expression patterns between PZQ-refractory juvenile flukes and PZQ-sensitive 
adults indicated that immature worms exhibited greater transcriptomic flexibility, potentially 
providing a means by which schistosomula could tolerate and survive exposure to this drug [161].  
We suggest that there are three main drug-discovery strategies which could be employed:  (i) the 
development of more effective derivatives of PZQ; (ii) the identification of novel compounds which 
act on the same target(s) as PZQ; or (iii) the identification of completely new targets and compounds 
which act on them. 
The design of novel anthelmintics, based on the structure of the PZQ molecule has been attempted 
by a number of groups, with varying success. Several analogues of PZQ were synthesised via 
modification of the aromatic ring (Fig. 3), but each of these analogues exhibited reduced potency 
compared to the parent drug [162]. Conversely, a 10-hydroxy (hydroxylation at position 10 of the 
aromatic ring) PZQ-artesunate hybrid (Fig. 3) has activity not only against S. japonicum adults, but also 
against PZQ-refractory juveniles [163]. (Note that artemisinin and related compounds alone also have 
anti-schistosomal activity [164, 165].)  There have been other attempts to vary the PZQ structure to 
produce novel antischistosomal drugs and to understand structure-activity relationships (reviewed 
recently by da Silva et al. [26]).  To date, none of these are in widespread clinical use.  This approach 
may be limited, however.  When widespread resistance to PZQ emerges, it may also result in 
resistance to many PZQ derivatives.  By analogy with bacterial resistance to antibiotics, it may be 
assumed that there are three main ways in which resistance may arise:  modification of the target 
which reduces the affinity for the drug, breakdown or modification of the drug to an inactive form, or 
enhanced transport of the drug out of the organism.  All of these involve interaction between the drug 
and biomolecules from the parasite.  All are likely to be effective with molecules which have a similar 
structure to PZQ.  Even where this does not occur (or the effect is minimal), the evolutionary distance 
to more effective resistance is likely to be short.  Again, by analogy with microbial antibiotic resistance, 
β-lactamase enzymes are effective not just against penicillin, but also a wide variety of its derivatives 
[166]. 
Knowledge of the PZQ mechanism of action would enable the design of small drug-like molecules 
which interfere with, or alter the function of the desired molecular target, serving to “phenocopy” the 
effects of PZQ [111].  The lack of definitive knowledge of the molecular mechanism of PZQ limits 
attempts to discover other compounds with similar mechanisms.  However, the unusual subunit 
structure of schistosome voltage gated calcium channels combined with the critical role of calcium 
ions in signalling makes them an attractive target for novel drug discovery regardless.  Targeting these 
channels would result is disruption of calcium ion homeostasis.  Either a failure to transport enough 
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calcium into the cells or uncontrolled influx are likely to be detrimental to the parasite.  Insufficient 
calcium would result in the failure of processes requiring the ion as a second messenger and the 
misfolding of proteins which require calcium to maintain their structure.  Excessive influx would lead 
to inappropriate, uncontrolled stimulation of calcium-mediated pathways such as muscle contraction 
and apoptosis.  Thus, developing biochemical systems to permit study of the schistosome voltage-
gated calcium channels should be considered a priority in research.  As membrane proteins, they are 
inevitably more difficult to work with and to express in recombinant systems than soluble, globular 
proteins.  It may be necessary to work with them in model systems such as Xenopus oocytes or yeast 
[167, 168].  Once established, both systems would enable the relatively rapid screening for antagonists 
in multiwall formats. 
While the preponderance of evidence favours a molecular mechanism in which PZQ disrupts calcium 
signalling, it should be noted that the other potential targets may also be interesting for future drug 
discovery.  Antagonism of myosin light chain function would disrupt the muscles of the parasite, most 
likely resulting in loss of motility.  Little is known about this protein in schistosomes.  However, it 
appears to be distantly related to mammalian myosin regulatory light chains and its sequence shows 
greater similarity to a different myosin light chain isoform in mammals, the essential light chain (43% 
identity to the most similar human myosin essential light chain compared to approximately 30% for 
regulatory light chains) [134].  This low level of sequence similarity suggests structures which may be 
different enough to enable species selective antagonists to be discovered.  It also suggests that there 
may be differences in the details of the regulation of muscle contraction between parasite and host 
which could also be exploited in drug discovery.  Indeed, it has been shown that the ultrastructure of 
schistosome muscle filaments more closely resembles that seen in arthropods than mammals, 
suggesting significant differences in the regulatory mechanisms [169].  By a similar argument, 
targeting adenosine uptake may also be worth further investigation. 
It may also be prudent to look for de novo drug targets which may, or may not be, related to the PZQ 
mechanism of action. For example, using the previously described comparative analyses, in 
combination with extensive drug screens and/or RNAi technology, it may be possible to identify novel 
target molecules which are unique to the parasite, essential for parasite survival and amenable to 
pharmacological intervention. In these respects, the components of parasite calcium signalling 
pathways represent putative candidates in their own right, regardless of their involvement in the PZQ 
mechanism of action. First, calcium signalling is an essential process in all eukaryotic cells [170], and 
second, anthelmintics that target the neuromuscular system of the parasite (and in particular, the ion 
channels that underlie the neuromuscular system) have a proven track record. Indeed, ion channels 
serve as the molecular targets for numerous anthelmintic drugs [129, 171]. Thus, molecules that play 
an important role in these pathways, yet are unique to the parasite (or sufficiently different from their 
counterparts/homologues in mammals), represent attractive targets for future drug development 
programs.  It may also be worth revisiting the modes of action of less commonly used anti-
schistosomal drugs.  Oxamniquine appears to act through modification of parasite DNA following 
modification by a parasite-specific enzyme [30].  It may be possible to discover other compounds with 
similar mechanisms.  Interrogation of the (extensive) literature on anti-cancer drug discovery may be 
fruitful here since a number of anti-cancer agents work by similar mechanisms [172].  There may be 
compounds which have failed as anti-cancer drugs, but which may be useful leads as anti-
schistosomals.  Prior to the use of OXA and PZQ, antimony compounds were used in the treatment of 
human schistosomiasis.  These were discontinued largely due to their severe side-effects [173].  One 
target of these agents is believed to be the glycolytic enzyme phosphofructokinase [174, 175].  
Clorsulon, a drug largely used to treat helminth infections in animals, also targets glycolytic enzymes, 
in this case phosphoglycerate mutase and phosphoglycerate kinase [176-178].  This compound has 
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some activity against S. mansoni, although it is not as effective as PZQ [179, 180].  Therefore, a 
renewed focus on studying and targeting metabolic enzymes and processes in schistosomes may also 
be a worthwhile strategy [181].  While the identification of novel targets provides the greatest scope 
for the discovery of new anti-schsitosomal drugs, the variety and diversity of possibly targets is 
considerable.  It is likely that this approach would require the greatest investment of time (and money) 
to yield results. 
 
Conclusions 
PZQ has been a remarkably successful drug.  It is taken by millions of people each year, has high cure 
rates and low reported side-effects.  Despite being used for decades, there are no conclusive reports 
of resistance emerging in a clinical setting.  However, PZQ is the only drug in common use to treat 
schistosomiasis, a disease which afflicts hundreds of millions of people globally.  If (or when) 
resistance does emerge, there is no alternative with comparable efficacy to PZQ.  Our ability to 
respond to that situation will be hampered by the significant unanswered questions about this drug: 
1. What is PZQ’s molecular target (or targets)? 
2. Where, and how, does PZQ interact with its target(s)? 
3. Why is R-praziquantel the active form?  Why does S-praziquantel result in side-effects and a 
bitter taste? 
4. Which of the observed consequences of PZQ administration represent direct results of the 
drug-target interaction and which result from the general dysregulation of the parasite’s 
physiology? 
5. How do the various subunits of schistosome voltage-gated calcium channels collaborate to 
function? 
6. How does the regulation of these voltage-gated calcium channels differ from the situation in 
mammals? 
7. Do the observations that PZQ binds to, or affects, myosin subunits, adenosine uptake and 
SmTAL1 have any significance for the mechanism of action? 
8. Why has resistance been so slow to emerge to PZQ?  Does this reflect something special or 
unusual about the molecular mechanism? 
9. If resistance did occur, which molecular mechanisms are likely? 
10. Why are some trematode species (e.g. F. hepatica) refractory to treatment by PZQ? 
Addressing these questions will require a concerted effort to understand the fundamental 
biochemistry of the organism, particularly in regards to calcium signalling.  A deeper understanding 
of the basic biology of schistosomes should facilitate both mechanistic studies on PZQ and the 
rational identification of further drug targets in the parasite.  The highly successful use of PZQ 
suggests that alternative drugs with the same or related targets may also be effective.  Thus, the 
need to understand PZQ’s mechanism of action is not just a basic science need, but also has the 
potential to catalyse the development of the next generation of anti-schistosomal drugs. 
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Figure legends 
Figure 1:  The life cycle of schistosomes.  The organism infects two animals, an intermediate snail 
host and the definitive human host.  Other mammals can also act as definitive hosts.  The life cycle is 
broadly similar for the three main species of schistosomes.  However, the mode of exit of the eggs 
differs.  Schistosoma mansoni and Schistosoma japonicum eggs are passed largely in the faeces 
whereas Schistosoma haematobium eggs are passed largely in the urine. 
Figure 2:  Current drugs for treating schistosomiasis.  The structures of R-praziquantel (the 
pharmacologically active isomer) and oxaminquine are shown. 
Figure 3:  Some examples of new compounds with antischistosomal activity.  (a) The praziquantel 
framework has been modified at the positions indicated by R1 and R2.  R1 variations included amino 
and nitro groups and R2 variations included cyclohexanyl, 3-aminobenzyl, 4-aminobenzyl and 4-
hydroxycyclohexanyl groups.  None of the compounds had better efficacy than PZQ in worm killing 
or paralysis assays with S. mansoni [162].  (b) 10-hydroxypraziquantel has increased efficacy against 
both juvenile and adult S. japonicum.  Furthermore, using the 10-hydroxyl group to conjugate the 
PZQ derivative to artemisinins also increased efficacy, presumably due to the combined effects of 
the two drugs [163]. 
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Eggs hatch; miracidia released
Miracidia enter snail 
(intermediate host)
Sporocysts develop in snail
Cercariae (free swimming) 
released from snail
Cercariaie penetrate human skin 
(definitive host)
Cercariae lose tails to 
become schistomulae
Schistomulae circulate in the blood
Schistomulae enter liver 
and mature into adultsAdults pair and produce eggs
Eggs released into environment 
via urine or faeces
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Gene Channel sub-type Type Tissue location(s) 
CACNA1S Cav1.1 L Skeletal muscle 
CACNA1C Cav1.2 L Cardiac and smooth muscle 
CACNA1D Cav1.3 L CNS and endocrine cells 
CACNA1F Cav1.4 L Skeletal muscle 
CACNA1A Cav2.1 P/Q CNS, heart, pituitary, dendrites and 
presynaptic terminals 
CACNA1B Cav2.2 N CNS, cell bodies, dendrites and 
presynaptic terminals CACNA1E Cav2.3 R 
CACNA1G Cav3.1 T CNS, heart, placenta, lung, kidney 
CACNA1H Cav3.2 T CNS, heart, placenta, lung, kidney 
CACNA1I Cav3.3 T CNS, heart, placenta, lung, kidney 
 
Table 1:  Mammalian Cav channel sub-types.  Channel types:  L-type, long-lasting current; P/Q-type, 
Purkinje fibre located/cerebellar granule neuron-located; N-type, neural; R-type, residual current; T-
type, transient current.  L- P/Q- and N-types are high voltage activated (HVA) channels, R-type 
channels are intermediate voltage activated (IVA) and T-type are low voltage activated (LVA). 
